
This study, focusing on advanced melanoma patients (July 2017–June 2020) from the Netherlands Cancer Registry who died before July 2020, analyzed systemic therapy timing and usage. Among 1097 patients, 68% received systemic therapy, with 25% initiating a new therapy within 90 days before death. Factors affecting therapy odds included female sex, elevated LDH, BRAF mutation, and poor performance status. The study underscores the need for shared decision-making in considering benefits and drawbacks, especially for those starting systemic therapy close to death.
Like
Save
Share